Abstract:THESIS 11122%%%%The objective of this project was to explore clinical and molecular aspects of electroconvulsive therapy (ECT) in the treatment of depression, with a particular focus on the role of microRNAs (small, non-coding molecules that can regulate gene expression). The patients receiving ECT in this study were participants in a randomised controlled trial (the EFFECT-Dep Trial) of high-dose (6x seizure threshold) right unilateral and standard dose (1.5x seizure threshold) bitemporal brief-pulse ECT for depression. The objective of the EFFECT-Dep Trial was to compare the effectiveness and cognitive side-effects of these two forms of ECT. In this thesis, a systematic review and meta-analysis was carried out with a similar objective. PubMed, PsycInfo, Web of Science, Cochrane Library, Embase and the International Clinical Trials Registry Platform databases were searched for with the terms "electroconvulsive" or "electroshock" and "trial". Seven randomised controlled trials (n=792) met inclusion criteria, including the EFFECT-Dep Trial. Bitemporal ECT did not differ from high-dose unilateral ECT on depression rating change scores (Hedges?s g = -0.03; 95% confidence interval (CI) -0.17 to 0.11), remission (RR 1.06; 95% CI 0.93 to 1.20), or relapse at 12-months (RR 1.42; 95% CI 0.90 to 2.23). There was an advantage for unilateral ECT on reorientation time after individual ECT sessions (mean difference in minutes = -8.28; 95% CI -12.86 to -3.70) and retrograde autobiographical memory (Hedges?s g =-0.46, 95% CI=-0.87 to -0.04) after completing an ECT course. There were no differences for general cognition, category fluency and delayed visual and verbal memory. The immediate clinical implication of this is that high-dose right unilateral ECT should be considered as a first-line option when prescribing ECT. Peripheral blood samples from patients participating in the EFFECTDep Trial and healthy controls were collected in PaxGene? bottles. MicroRNAs and mRNAs were extracted using PaxGene? blood miRNA/RNA kits. An initial discovery phase deep sequencing study (n=16) was carried out on the SOLiD? platform. This yielded over 23 million reads mapping on to known microRNAs in the human genome. However, in the group as a whole there were no significant differences in microRNA levels from baseline to ECT following strict correction for multiple testing. However, post-hoc analysis indicated that there were significant changes in microRNA levels in patients with psychotic depression. These changes were confirmed in the same sample using quantitative real-time polymerase chain reaction (qRTPCR). In a separate cohort (37 depressed, 34 controls), candidate microRNAs from deep sequencing were analysed in a validation study. Two microRNAs (miR-126-3p and miR-106a-5p) were significantly elevated in patients with psychotic depression (n=7) at baseline when compared to healthy controls. After ECT treatment, the levels of these microRNAs normalised. Bioinformatic analysis revealed a high number of genes, molecular and biological processes…

Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression

Electroconvulsive therapy for depression : optimising treatment and exploring molecular mechanisms

Blood Mir-144-3p: a Novel Diagnostic and Therapeutic Tool for Depression

Electroconvulsive Therapy Changes Immunological Markers in Patients With Major Depressive Disorder

Peripheral blood SIRT1 mRNA levels in depression and treatment with electroconvulsive therapy

Abnormal Expression Profile of Plasma-Derived Exosomal Micrornas in Patients with Treatment-Resistant Depression

Molecular basis underlying changes of brain entropy and functional connectivity in major depressive disorders after electroconvulsive therapy

Altered In vivo early neurogenesis traits in patients with depression: Evidence from neuron-derived extracellular vesicles and electroconvulsive therapy

Serum Angioneurin Levels Following Electroconvulsive Therapy for Mood Disorders

Exploring the effects of erythropoietin treatment on cortical thickness and hippocampal volume in patients with mood disorders undergoing electroconvulsive therapy: A randomized, placebo-controlled trial

Gene expression of kynurenine pathway enzymes in depression and following electroconvulsive therapy

Electroconvulsive therapy regulates brain connectome dynamics in patients with major depressive disorder

Increased Mir-132 Level is Associated with Visual Memory Dysfunction in Patients with Depression

Unraveling epigenomic signatures and effectiveness of electroconvulsive therapy in treatment-resistant depression patients: a prospective longitudinal study

Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis

Changed brain entropy and functional connectivity patterns induced by electroconvulsive therapy in majoy depression disorder

Neuroimaging Biomarkers at Baseline Predict Electroconvulsive Therapy Overall Clinical Response in Depression: A Systematic Review

Brain-derived neurotrophic factor blood levels after electroconvulsive therapy in patients with mental disorders: A systematic review and meta-analysis

Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy

Electroconvulsive Therapy-Induced Changes in Functional Brain Network of Major Depressive Disorder Patients: A Longitudinal Resting-State Electroencephalography Study

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study